Thimerosal - CAS# 54-64-8

Thimerosal, a mercury-containing vaccine preservative, is a suspected factor in the etiology of neurodevelopmental disorders.

Product information

CAS Number: 54-64-8

Molecular Weight: 404.81

Formula: C9H9HgNaO2S

Chemical Name: sodium;(2-carboxylatophenyl)sulfanyl-ethylmercury

Smiles: [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O

InChiKey: RTKIYNMVFMVABJ-UHFFFAOYSA-L

InChi: InChI=1S/C7H6O2S.C2H5.Hg.Na/c8-7(9)5-3-1-2-4-6(5)10;1-2;;/h1-4,10H,(H,8,9);1H2,2H3;;/q;;2*+1/p-2

Technical Data

Appearance: Solid Power

Purity: ≥98% (or refer to the Certificate of Analysis)

Solubility: H2O : 100 mg/mL (229.95 mM; Need ultrasonic and warming).

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 ^oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥12 months if stored properly.

Stock Solution Storage: 0 - 4 ^oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined

HS Tariff Code: 382200

How to use

In Vivo:

The Thimerosal (THIM) administration increases μ-opioid receptors (MORs) density in the periaqueductal gray (PAG) in a dose-dependent manner. Treatment with higher doses of Thimerosal statistically significantly increases MOR density in the dorsomedial periaqueductal gray (DMPAG) and lateral periaqueductal gray (LPAG) regions. At the dose 3,000 μg Hg/kg, Thimerosal also augments MOR density in the caudate putamen (CPU). In contrast, the administration of Thimerosal at both higher doses decreases MOR density in the dentate gyrus (DG). Thimerosal administration (4 injections, i.m., 240 μg Hg/kg on postnatal days 7, 9, 11, 15) induces lasting changes in amino acid overflow: an increase of glutamate and aspartate accompanied by a decrease of glycine and alanine; measured 10 to 14 weeks after the injections. Four injections of Thimerosal at a dose of 12.5 μg Hg/kg do not alter glutamate and aspartate concentrations at microdialysis time. Application of Thimerosal to the prefrontal cortex (PFC) in perfusion fluid evokes a rapid increase of glutamate overflow. Coadministration of the neurosteroid, dehydroepiandrosterone sulfate (DHEAS; 80 mg/kg; i.p.) prevents the Thimerosal effect on glutamate and aspartate; the steroid alone has no influence on these amino acids. Coapplication of dehydroepiandrosterone sulfate (DHEAS) with Thimerosal in perfusion fluid also blocks the acute action of Thimerosal on glutamate.

Products are for research use only. Not for human use.